• No results found

University of Groningen Genomic heterogeneity of clear cell renal cell carcinoma Ferronika, Paranita

N/A
N/A
Protected

Academic year: 2021

Share "University of Groningen Genomic heterogeneity of clear cell renal cell carcinoma Ferronika, Paranita"

Copied!
2
0
0

Bezig met laden.... (Bekijk nu de volledige tekst)

Hele tekst

(1)

University of Groningen

Genomic heterogeneity of clear cell renal cell carcinoma

Ferronika, Paranita

DOI:

10.33612/diss.101437783

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version

Publisher's PDF, also known as Version of record

Publication date: 2019

Link to publication in University of Groningen/UMCG research database

Citation for published version (APA):

Ferronika, P. (2019). Genomic heterogeneity of clear cell renal cell carcinoma. Rijksuniversiteit Groningen. https://doi.org/10.33612/diss.101437783

Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

Take-down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.

(2)

Every tumour is unique (this thesis).

ccRCC is initiated by the loss of short arm of chromosome 3 and the inactivation of the VHL-HIF pathway (Sato Y et al. Nat Genet 2013; 45: 860-867).

Not all driver mutations in ccRCC have the same impact on patient survival

(this thesis).

Only multiple tumour sampling allows us to determine the trunk mutations

(this thesis).

Metastasis development could start from a punctuated evolution in a subregion of a primary tumour (this thesis).

Polyclonal seeding may be a major cause of intra-patient metastasis heterogeneity (this thesis).

Intratumour heterogeneity is a reflection of dynamic evolution of the tumour cells (Dagogo-Jack I, Shaw AT. Nat Rev Clin Oncol 2018; 15: 81-94.).

Evolution thus is merely contingent on certain processes articulated by Darwin: variation and selection (Ernst Mayr).

You are always being presented with two choices: evolve or repeat (ancient

wisdom). 1. 2. 3. 4. 5. 6. 7. 8. 9.

Paranita Ferronika, Groningen 2019 Propositions

Genomic heterogeneity of

Referenties

GERELATEERDE DOCUMENTEN

In chapter 4, we describe a study in which we extensively analysed one ccRCC case using samples from multiple regions of the primary tumour, a sample from a tumour thrombus

For the detection of variants in specific genes, including known ccRCC cancer driver genes or even specific variants (i.e. hotspot analysis), targeted sequencing is more suitable

a Adjusted for age at diagnosis (years) and sex b Adjusted for age at diagnosis (years), sex, TNM stage, differentiation grade and tumor size c Adjusted for age at diagnosis

Association of VEGF and VEGFR2 single nucleotide polymorphisms with hypertension and clinical outcome in metastatic clear cell renal cell carcinoma patients treated with

(a) Empirical Bayes estimates of clearance of sunitinib (CLp) and the active metabolite SU12662 (CLm) for base model stratified by different genotypes of single

Supplementary Table 1 – Overview of single nucleotide polymorphisms and haplotypes in candidate genes related to the pharmacokinetics and pharmacodynamics of sunitinib that were

Finally, we attempted to assess whether VHL loss, CDKN2A loss and MYC activation are dysregulated at tumour initiation or tumour progression, by analysing their relative frequency

The goal of this research is to benchmark the results of the gene expression reversal analysis of the tumour subtype and the individual tumour sample signatures against the results